UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934
Date of report (Date of earliest event reported): August 11, 2020
BIOTRICITY INC.
(Exact name of registrant as specified in its charter)
| Nevada | | 000-56074 | | 47-2548273 |
(State or Other Jurisdiction of Incorporation or Organization) | | (Commission File Number) | | (IRS Employer Identification No.) |
275 Shoreline Drive, Suite 150
Redwood City, California 94065
(Address of Principal Executive Offices)
(650) 832-1626
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| | Securities registered pursuant to Section 12(b) of the Act: note |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | |
| | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [X] |
| | |
| | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X] |
Item8.01 Other Events.
On August 11, 2020(the “Execution Date”) Biotricty Inc. (the “Company”) executed a Definitive Agreement of Understanding with MD Matrix Inc. The agreement of understanding sets forth the term upon which the parties would enter into a license agreement pursuant to which he Company would license MDM’s core technology and pursuant to which the Company would have the right to acquire the MDM technology. The terms of the Agreement of Understanding expire ninety days after the Execution Date.
The foregoing descriptions of the Agreement of Understanding is qualified by reference to the full text of such document which is filed as exhibits to this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 13, 2020
| | BIOTRICITY INC. |
| | | |
| | By: | /s/ Waqaas Al-Siddiq |
| | | Waqaas Al-Siddiq Chief Executive Officer |
